Increasing demand for the prophylactic treatment to improve infusion of blood clotting factors for the haemophiliac patients is fuelling market penetration across the globe. It occurs in approximately one in 5,000 childbirth annually. Improved R&D along with the advanced medical science and drug therapies provides effective treatment for spontaneous bleeding by maintaining clotting level is among key factors fuelling the Hemophilia A therapeutics market growth.
Painful symptoms such as swelling joints, neck pain, fatigue, and prolonged headache are among the major signs of hemophilia. Although there is no cure of haemophilia some therapies along with effective medicines are widely used according to the type. Higher cost and expensive drugs therapies and lack of awareness in emerging countries may hinder future growth prospects.
Global hemophilia A therapeutics market is segregated on the basis of product as, desmopressin, octocogalfa, and nonacogalfa. Global hemophilia A therapeutics market report provides geographic analysis covering regions such as North America, Europe, Asia Pacific, and Rest of World. The hemophilia A therapeutics market for each region is further segmentedfor major countries including U.S., Canada, Germany, UK, France, Italy, China, India, Japan, Brazil, South Africa and others.
Competitive Rivalry
Expression Therapeutics, Genetics Institute, Pfizer, Bayer AG, Alpha Therapeutics Corporation, Novo Nordisk A/S, Alpha Therapeutics Corporation, Baxter International Inc, Swedish Orphan Biovitrum AB, and Biogen Idec are among the major players in the global hemophilia A therapeutics market share. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The Hemophilia A Therapeutics Market has been segmented as below:
Hemophilia A Therapeutics Market, By Drugs
Hemophilia A Therapeutics Market, By Region
The report covers:
Report scope:
Global haemophilia A therapeutics market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global haemophilia A therapeutics market share. Major industry players with significant revenue share include Expression Therapeutics, Genetics Institute, Pfizer, Bayer AG, Alpha Therapeutics Corporation, Novo Nordisk A/S, Alpha Therapeutics Corporation, Baxter International Inc, Swedish Orphan Biovitrum AB, and Biogen Idec.
Reasons to Buy this Report:
Customization:
Customized report as per the requirement can be offered with appropriate recommendations
Below are our New Reports :-
1. Introduction
1.1. Key Points
1.2. Report Description
1.3. Markets Covered
1.4. Stakeholders
2. Research Methodology
2.1. Research Scope
2.2. Research Methodology
2.2.1. Market Research Process
2.2.2. Research Methodology
2.2.2.1. Secondary Research
2.2.2.2. Primary Research
2.2.2.3. Models for Estimation
2.3. Market Size Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Drivers
4.2.1. Driver 1
4.2.2. Driver 2
4.2.3. Driver 3
4.3. Restraints
4.3.1. Restraint 1
4.3.2. Restraint 2
4.4. Opportunities
4.4.1. Opportunity 1
4.4.2. Opportunity 2
4.5. Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
5. Hemophilia A Therapeutics Market, By Drugs
5.1. Key Points
5.2. Desmopressin
5.3. Octocogalfa
5.4. Nonacogalfa
6. Competitive Landscape
6.1. Introduction
6.2. Recent Developments
6.2.1. Mergers &Acquisitions
6.2.2. New Product Developments
6.2.3. Portfolio/Production Capacity Expansions
6.2.4. Joint Ventures, Collaborations, Partnerships & Agreements
6.2.5. Others
7. Company Profile
7.1. Expression Therapeutics
7.1.1. Company Overview
7.1.2. Product/Service Landscape
7.1.3. Financial Overview
7.1.4. Recent Developments
7.2. Genetics Institute
7.2.1. Company Overview
7.2.2. Product/Service Landscape
7.2.3. Financial Overview
7.2.4. Recent Developments
7.3. Pfizer
7.3.1. Company Overview
7.3.2. Product/Service Landscape
7.3.3. Financial Overview
7.3.4. Recent Developments
7.4. Bayer AG
7.4.1. Company Overview
7.4.2. Product/Service Landscape
7.4.3. Financial Overview
7.4.4. Recent Developments
7.5. Alpha Therapeutics Corporation
7.5.1. Company Overview
7.5.2. Product/Service Landscape
7.5.3. Financial Overview
7.5.4. Recent Developments
7.6. Novo Nordisk A/S
7.6.1. Company Overview
7.6.2. Product/Service Landscape
7.6.3. Financial Overview
7.6.4. Recent Developments
7.7. Alpha Therapeutics Corporation
7.7.1. Company Overview
7.7.2. Product/Service Landscape
7.7.3. Financial Overview
7.7.4. Recent Developments
7.8. Baxter International Inc
7.8.1. Company Overview
7.8.2. Product/Service Landscape
7.8.3. Financial Overview
7.8.4. Recent Developments
7.9. Swedish Orphan Biovitrum AB
7.9.1. Company Overview
7.9.2. Product/Service Landscape
7.9.3. Financial Overview
7.9.4. Recent Developments
7.10. Biogen Idec
7.10.1. Company Overview
7.10.2. Product/Service Landscape
7.10.3. Financial Overview
7.10.4. Recent Developments
The Hemophilia A Therapeutics Market has been segmented as below:
Hemophilia A Therapeutics Market, By Drugs
Hemophilia A Therapeutics Market, By Region
SUBSCRIBE TO OUR NEWSLETTERS
